Relationship between human BSEP inhibition potency and physicochemical properties for 85 pharmaceuticals
| Category | No. of Drugs in Category (% total) | Prevalence of Drugs with hBSEP IC50 <300 μM |
|---|---|---|
| All drugs | 85 (100) | 0.39 |
| Mol. wt. >250 | 57 (67) | 0.58 |
| CLogP >1.5 | 54 (64) | 0.61 |
| NPSA >180 | 64 (75) | 0.52 |
| CLogP >1.5 and NPSA >180 | 51 (60) | 0.65 |
| Mol. wt. >250 and NPSA >180 | 54 (64) | 0.61 |
| Mol. wt. >250 and CLogP >1.5 | 43 (51) | 0.77 |
| Mol. wt. >250 and CLogP >1.5 and NPSA >180 | 43 (51) | 0.77 |